YOUR HOST: DISCLOSURE




Jia Hu

Public health & preventive medicine physician and family physician Co-founder, 19 To Zero Adjunct professor, University of Calgary

Disclosures

• I have received research/operational funding and other honoraria from the following pharmaceutical companies: GSK, Pfizer, Merck Moderna, Sanofi, Novavax, and Seqirus

A snapshot of last influenza season – early & fast – that combined with RSV & COVID-19 led to a 'tripledemic'




Calgary Zone webinar series: Mental health & hot topics

Calgary Zone webinar series: Mental health & hot topics

We look to the Southern Hemisphere to predict what will happen for our respiratory seasons • Australia's winter occurs during

Notifications of laboratory-confirmed influenza, Australia, January 2016 – August 2023, by month and week of diagnosis¹



- Australia's winter occurs during June/July/August and is often used to predict what will happen during our winter months
- In 2020/2021, there were virtually no cases of influenza – indicating that COVID-19 lockdowns were highly effective at stopping nearly all transmission of the less infectious influenza virus
- In the 2023 Australia season (it is currently winter there) – they appear to have had an early start to the season which has since tapered down
- It is a bit early to draw conclusions about what we will see in our fall/winter 2023, but we know immunization will always be the best way to protect oneself


Source: Australian Government National Notifiable Diseases Surveillance System, Australian Influenza Surveillance Report and Activity Updates (2023)

🛃.csv


Calgary Zone webinar series: Mental health & hot topics

COVID-19 levels have been on the rise through September

Figure 5. Daily number of hospital beds and ICU beds occupied by COVID-19 patients as of October 3, 2023



Population normalized quantity of SARS CoV-2 virus over time



 COVID-19 hospitalizations across Canada are increasing this fall (from nadir of ~1,500 to current levels of ~3,500)

> And there is also a trend of increasing COVID-19
> levels per wastewater
> surveillance in Alberta


Other

VACCINATION: FALL/WINTER RESPIRATORY SEASON

Calgary Zone webinar series: Mental health & hot topics

New variants have been circulating, but all XBB family

- On August 9, the WHO declared **EG.5** (or • Eris) a "variant of interest", but said it did not seem to most more of a threat to public health than others
- EG.5 is a descendant of the XBB.1.9.2 lineage (the XBB family has been the dominant circulating variants in 2023)
- Another variant, BA.2.86 (from the BA.2) lineage) has been circulating recently and is known to have 30+ mutations – its clinical significant is not yet known
- Currently, virtually all COVID-19 in • Canada is either XBB or EG.5




Week of sample collection

Source: Globe and Mail EG.5 Explainer (https://www.theglobeandmail.com/canada/article-new-covid-variant-eg5/); What to know about COVID Pirola (https://www.usatoday.com/story/news/health/2023/08/21/pirola-covid-lineage-not-omicron-variant/70644689007/); Canada Health Infobase (https://health-infobase.canada.ca/covid-19/);

Calgary Zone webinar series: Mental health & hot topics

... but influenza levels are pretty low

Total weekly laboratory-confirmed seasonal influenza cases by subtype in Alberta, 2019-2020 to 2023-2024



Source: Canada Health Infobase (<u>https://health-infobase.canada.ca/covid-19/</u>); Alberta respiratory virus surveillance dashboard (https://www.alberta.ca/stats/dashboard/respiratory-virus-dashboard.htm)

Calgary Zone webinar series: Mental health & hot topics

Vaccinations for the fall respiratory season

Publicly funded

- COVID-19 recommended for everyone 6 months and older
 - XBB monovalent formulation this year from Pfizer/Moderna/Novavax
- Influenza recommended for everyone 6 months and older
 - Standard dose quadrivalent for 65 and under, high-dose quadrivalent for 65 and higher

Not publicly funded


- RSV new vaccine (Arexvy), recently approved by Health Canada for 60+, no NACI statement yet; also, Nirsevimab for infants (very limited supply this year, hospital only for now)
- Pneumococcal new(ish) vaccine PCV20 recommended for everyone 65+ and younger with certain medical conditions

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: COVID-19

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

Guidance on the use of COVID-19 vaccines in the fall of 2023



Beginning in the fall of 2023 for those previously vaccinated against COVID-19, NACI recommends a dose of the <u>NEW</u> <u>FORMULATION OF COVID-19 VACCINE (XBB MONOVALENT)</u> for individuals in the authorized age group <u>if it has been at least 6</u> <u>months from the previous COVID-19 vaccine or known SARS-</u> <u>CoV-2 infection (whichever is later)</u>

Immunization is particularly important for those at increased risk of COVID-19 infection / severe disease, including:

- Adults 65 and older
- Residents of LTC / congregate living settings
- Individuals with underlying medical conditions that place them at higher risk of severe COVID-19
- Individuals who are pregnant
- Individuals in or from First Nations, Metis, and Inuit Communities
- Members of racialized and other equity-deserving communities
 - People who provide essential community services

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: Influenza


Recipien t by age group	Vaccine types available for use ^{**}	Recommendations on choice of influenza vaccine	
	 IIV3-SD – trivalent standard dose IIV3-Adj – trivalent 	Individual-level Decision-making	Public health program-level Decision-making
65 years and older	 IIV3-Adj – trivalent adjuvanted IIV4-SD - quadrivalent standard dose IIV4-HD – quadrivalent high dose IIV4-cc – quadrivalent cell culture RIV4 – quadrivalent recombinant 	 <u>IIV-HD should be used over IIV-SD,</u> given the burden of influenza A(H3N2) disease and the good evidence of IIV3-HD providing better protection compared to IIV3- SD in adults 65 years of age and older. Other than a recommendation for using IIV-HD over IIV-SD formulations, NACI has not made comparative individual-level recommendations on the use of the other available vaccines in this age group. In the absence of a specific product, any of the available age-appropriate influenza vaccines should be used. 	Any of the available influenza vaccines should be used. There is insufficient evidence on the incremental value of different influenza vaccines (i.e. cost-effectiveness assessments have not been performed by NACI) to make comparative public health program-level recommendations on the use of the available vaccines.

Source: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022–2023.

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: Influenza


Flu prevention by influenza vaccines in younger and older persons over 7 seasons¹



Average vaccine effectiveness by age from the French Sentinel Network, 1998-2005. Adapted from Legrand, J., et al. (2006).¹

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: RSV



Virtually all children will have been infected with RSV by age 2 years¹ Immune response after natural infection is incomplete and is short-lived^{2,3}. RSV reinfections occur throughout life³ Older adults are at high risk of severe RSV infection. Those with underlying medical conditions are at even greater risk^{4,5}

Source: Centers for Disease Control and Prevention (CDC), 2020. Respiratory syncytial virus infection (RSV): symptoms and care. <u>http://www.cdc.gov/rsv/about/symptoms.html</u> (accessed October 2022); Openshaw PJM *et al. Annu Rev Immunol* 2017;35:501–532;; Walsh E *et al. Clin Chest* Med 2017;38(1):29–36; 4. Branche AR *et al. Clin Infect Dis* 2022;74(6):1004-1011; Centers for Disease Control and Prevention (CDC), 2020. RSV in older adults and adults with chronic medical conditions. <u>https://www.cdc.gov/rsv/high-risk/older-adults.html</u> (accessed October 2022)

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: RSV (burden of disease)

RSV is the **leading cause of hospitalization** in infants

In children aged <5 years:

~58,000 hospitalizations,

~1.5 million outpatient visits~520,000 ED visits

100-500 deaths

RSV is a **major cause of hospitalization and mortality** in older adults

In older adults, ≥65 years:

~177,000 hospitalizations

Outpatient and ED visits in adults underestimated due to lack of surveillance and underreporting

~14,000 deaths



Source: National Foundation for Infectious Diseases (NFID), 2022. Call to action: reducing the burden of RSV across the lifespan. https://www.nfid.org/wp-content/uploads/2022/04/

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: RSV


- GSK's Prefusion F protein-based candidate vaccine with AS01_E adjuvant studied in ~24,966 participants
- NEJM publication released February 2023
- Vaccine efficacy against <u>PCR-confirmed RSV-related lower</u> respiratory tract disease was 82.6% overall, and 94.1% against severe RSV-related lower respiratory tract disease
- This vaccine was approved in Canada earlier this year for adults 60 and older
- No current NACI recommendation on its use (expected early 2024)
- List Price ~\$230, Total Price ~\$300
- Not publicly funded (only public funding in Canada is a LTC program in Ontario)

	ARCH SUMMARY
Respiratory Syncytial Virus Prefi	usion F Protein Vaccine in Older Adult
Papi A et al. Di	01: 33.1656/NE2Mau/201604
AND A PROBABIL	
ider adabs with requiratory sprayfiel virus (RSV) in- ction are at take of lower enspiratory must disease, po- stially leading to exacehation of underlying condi- rus, hespiralization, and death. There are no lineased	Registery Symptot Vina State
W vacuines or prophylactic interventions for older labs.	27 Constrains Fallwood Each RDV Sames Kontery Hanapaso 1.2 Constrains Fallwood Each RDV Sames Manapaso
ANCAL TROS	Endown Analytic and Particular Start
eign An orgoing phase 3, international, random- el, plaodse-controlled trial assessed the efficacy and dety of an ASOL, edgeanted sugaratory syncytial ri-	No. 1 for 1
n (RIV) prefusion # provisis-based conditione vaccine SVDvc15 OAU among adults 200 years of age.	14
revention: 25,040 participants in 17 countries were signed to receive a single door of the RSVProT3 OA come or placebo believe the RJV season. The priva- objective was to show vertice efficacy against RSV- land lower requirement time disease during one RJV rest.	RD Tentine (Files), 82.85. SD SC
EALTS	1.
Brasy During a median follow-up of 6.7 months, roug 30,000 periorports with evaluable data, survive Bracy apatter RJV-conformed lower respiratory teat sease was 20%.	Hereford Data
Rep Solicited adverse events occurred more often the the consister than with planches, more water mild to adentite in servicity and resolved within the 4-day an- titution preted. This was the most common solicited potime-site matrices with the succine, and brigger was a most common solicited systemic reaction.	Any volicited Any volicited adverse macrices Pain Pain Pain Pain Pain Pain Pain Pain Pain Pain Pain
INVERSING AND REMAINING DESTINAT	
A small number of finil participants and participants 280 years of ape were included; longer follow-up is medial to determine efficacy in these subgroups.	10 000 000 000 000 000 000 000 000 000
The trial had limited ability to detect rare side of- facts.	Bithell Rooks ISSNell Rooks Bithell Rooks
Public health measures to limit Covid-19 transmis- sion induced the spread of KSV and also of the RSV season.	CONCLUSIONS A single dose of an AMD, adjunanted RSV preliation T
Additional RNV seasons need to be studied to better	protein-board candidate meetine (ESWherFT OA) given

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: Pnuemococcal disease

Invasive pneumococcal disease serotype coverage for PCVs in Canadian Adults ≥ 65 Years of Age from NML 2019 (N=1476)




Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: Pneumococcal disease

An Advisory Committee Statement (ACS)

National Advisory Committee on Immunization (NACI)

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines



NACI recommends that pneumococcal conjugate vaccine PNEU-C-20 should be offered to pneumococcal vaccine naïve adults or adults whose vaccination status is unknown and who are

- 65 years of age and older,
- 50 to 64 years of age living with risk factors placing them at higher risk of pneumococcal disease,
- **18 to 49 years of age living** with immunocompromising conditions. (Strong NACI recommendation)

It's also a very cost-effective vaccine: "The base-case analysis, supported by scenario analyses, indicated that PNEU-C-20 used alone is likely a cost-effective strategy at age 65 or 75, with ICERs ranging from \$6,500 to \$17,400 per QALY gained."

Calgary Zone webinar series: Mental health & hot topics

Respiratory Season Vaccinations: Pneumococcal disease

An Advisory Committee Statement (ACS)

National Advisory Committee on Immunization (NACI)

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines




Table 1. Medical conditions and other biological and/or social risk factors resulting in high risk of IPD

Non-immunocompromising conditions	Immunocompromising conditions	Other risk factors
 Chronic cerebrospinal fluid (CSF) leak Chronic neurologic condition that may impair clearance of oral secretions Cochlear implants, including children and adults who are to receive implants Chronic heart disease Diabetes mellitus Chronic kidney disease a Chronic liver disease, including hepatic cirrhosis due to any cause a Chronic lung disease, including asthma requiring medical care in the preceding 12 months 	 Sickle cell disease, congenital or acquired asplenia, or splenic dysfunction Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions Immunocompromising therapy, including use of long-term corticosteroids, chemotherapy, radiation therapy, and post-organ transplant therapy HIV infection Hematopoietic stem cell transplant (recipient) Malignant neoplasms, including leukemia and lymphoma Nephrotic syndrome Solid organ or islet transplant (candidate or recipient) 	 Individuals who smoke who use illicit drugs with alcohol use disorder who are experiencing homelessness who live in communities or settings d experiencing sustained high IPD rates.

Note – fairly broad set of conditions put you at high-risk for IPD (invasive pneumococcal disease) for the Age 50-64 indication

Q&A

